=== Sample reports ===
{| class="wikitable" style="font-size:90%" border="1" cellpadding="5" cellspacing="0"
|- style="background:lightgrey"
!align = "center" bgcolor = "#00CCFF" width="10%" rowspan="2"|Item Number
!align = "center" bgcolor = "#00CCFF" colspan = "4" |Design Input
!align = "center" bgcolor = "#00CCFF" width="5%" rowspan="2"|Design Output
!align = "center" bgcolor = "#00CCFF" width="5%" rowspan="2"|Design Verification Report #
!align = "center" bgcolor = "#00CCFF" width="5%" rowspan="2"|Status (P/F/R)
!align = "center" bgcolor = "#00CCFF" width="5%" rowspan="2"|Design Validation Report #
!align = "center" bgcolor = "#00CCFF" width="5%" rowspan="2"|Status (P/F/R)
|-
!align = "center" bgcolor = "#00CCFF" width="20%"|User Needs
!align = "center" bgcolor = "#00CCFF" width="20%"|User Need Rationale
!align = "center" bgcolor = "#00CCFF" width="15%"|Engineering Specification
!align = "center" bgcolor = "#00CCFF" width="15%"|Engineering Specification Rationale
|-
!3.1.1
|Provide antimicrobial resistance for up to 2 weeks
|Ureteral Stent User Survey (Document #XXXXX)
|Stent must have chlorohexadine surface concentration of 10-20 mg/cm2 for 3 weeks
|Document #XXXXX
|Test Document #XXXXX
|Report 01-005-06-007
|P
|Report 01-005-06-007
|P
|-
|}
=== Potential DHF Review Outcomes ===